# Sangamo Therapeutics clinical trials: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Sangamo Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sangamo Therapeutics: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sangamo-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 20, 2025 | NCT06980948 | Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) | Sangamo Therapeutics | Phase 1/2 | Suspended | Chronic Neuropathic Pain | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980948) |
| August 14, 2023 | NCT05987527 | Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) | Sangamo Therapeutics | Observational | Active not recruiting | Kidney Transplant Rejection, End Stage Renal Disease | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05987527) |
| December 6, 2021 | NCT05145062 | Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. | Sangamo Therapeutics | Observational | Active not recruiting | Blood and Lymphatic Diseases | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05145062) |
| September 10, 2021 | NCT05039866 | Long-Term Follow-up of Subjects Who Were Treated With ST-920 | Sangamo Therapeutics | Observational | Active not recruiting | Fabry Disease, Fabry Disease, Cardiac Variant | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05039866) |
| March 26, 2021 | NCT04817774 | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients | Sangamo Therapeutics | Phase 1/2 | Completed | Kidney Transplant Rejection, End Stage Renal Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04817774) |
| November 16, 2020 | NCT04628871 | Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX | Sangamo Therapeutics | Observational | Terminated | Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04628871) |
| December 17, 2019 | NCT04201782 | Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T | Sangamo Therapeutics | Observational | Terminated | HIV-1-infection | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04201782) |
| August 6, 2019 | NCT04046224 | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | Sangamo Therapeutics | Phase 1/2 | Completed | Fabry Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04046224) |
| August 31, 2018 | NCT03653247 | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With... | Sangamo Therapeutics | Phase 1/2 | Completed | Sickle Cell Disease | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03653247) |
| February 14, 2018 | NCT03432364 | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) | Sangamo Therapeutics | Phase 1/2 | Completed | Transfusion Dependent Beta-thalassemia | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03432364) |
| February 2, 2017 | NCT03041324 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II | Sangamo Therapeutics | Phase 1/2 | Terminated | Mucopolysaccharidosis II, MPS II | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03041324) |
| March 8, 2016 | NCT02702115 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I | Sangamo Therapeutics | Phase 1/2 | Terminated | MPS I | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02702115) |
| March 1, 2016 | NCT02695160 | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B | Sangamo Therapeutics | Phase 1 | Terminated | Hemophilia B | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02695160) |
| August 26, 2014 | NCT02225665 | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART | Sangamo Therapeutics | Phase 1/2 | Completed | Human Immunodeficiency Virus (HIV) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02225665) |
| March 2, 2012 | NCT01543152 | Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T | Sangamo Therapeutics | Phase 1/2 | Completed | HIV | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01543152) |
| December 3, 2010 | NCT01252641 | Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | Sangamo Therapeutics | Phase 1/2 | Completed | HIV, HIV Infection | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01252641) |
| March 3, 2010 | NCT01079325 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | Sangamo Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01079325) |
| January 8, 2010 | NCT01044654 | Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | Sangamo Therapeutics | Phase 1 | Completed | HIV Infection, HIV Infections | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01044654) |
| September 28, 2009 | NCT00985517 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | Sangamo Therapeutics | Phase 1/2 | Completed | Idiopathic Parkinson's Disease | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00985517) |
| April 7, 2009 | NCT00876863 | Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease | Sangamo Therapeutics | Phase 2 | Completed | Alzheimer's Disease | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00876863) |
| September 8, 2008 | NCT00748501 | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Sangamo Therapeutics | Phase 2 | Completed | Amyotrophic Lateral Sclerosis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00748501) |
| April 23, 2008 | NCT00665145 | Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 | Sangamo Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00665145) |
| May 22, 2007 | NCT00476931 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | Sangamo Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00476931) |
| December 4, 2006 | NCT00406458 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | Sangamo Therapeutics | Phase 2 | Completed | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00406458) |
| November 17, 2006 | NCT00400634 | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease | Sangamo Therapeutics | Phase 2 | Completed | Idiopathic Parkinson's Disease | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00400634) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 11 |
| Phase 2 | 7 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 5 |
| Active not recruiting | 3 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetic Neuropathies | 5 |
| Diabetes Mellitus, Type 1 | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Parkinson Disease | 3 |
| Hemophilia B | 2 |
| Mucopolysaccharidosis I | 2 |
| Mucopolysaccharidosis II | 2 |
| Fabry Disease | 2 |
| beta-Thalassemia | 2 |
| Anemia, Sickle Cell | 2 |
| Kidney Failure, Chronic | 2 |
| Alzheimer Disease | 2 |
| HIV Infections | 2 |
| Lysosomal Storage Diseases | 1 |
| Fabry Disease, Cardiac Variant | 1 |
| Diabetes Mellitus | 1 |
| Dementia | 1 |
| Memory Disorders | 1 |
| Cognitive Dysfunction | 1 |
| Hereditary Sensory and Autonomic Neuropathies | 1 |
| Lymphatic Diseases | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Movement Disorders | 1 |
| Sudden Infant Death | 1 |
| Small Fiber Neuropathy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
